Embolization involves the percutaneous endovascular use of one or more of a variety of agents to treat laparoscopic, neurovascular, uterine fibroids, arteriovenous malformations, hepatocellular carcinoma, benign prostatic hyperplasia (BPH), neurovascular, Surgery involving intracranial and peripheral vasculature.
NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) — Reportlinker.com Announces Release of Report “Global Embolic Therapy Market – Forecast to 2029” – https://www.reportlinker.com/p06377911 /?utm_source=GNW
According to IQ4I analysis, the global embolization therapy market is expected to grow at a mid-single-digit CAGR from 2022 to 2029, reaching $6,115.9 million by 2029. The embolization products market is segmented into temporary agents, permanent agents, radioembolization, and assistive devices. Among them, permanent medications accounted for the largest share of his market in 2022 and from 2022 he is expected to grow at his CAGR of high single digits through 2029. The segment is expected to grow at a high single-digit CAGR from 2022 to 2029. Temporary drugs are further sub-segmented into autologous drugs and resorbable gelatin sponges. Of these, resorbable gelatin sponges will account for the largest share in 2022, with CAGR from 2022 to 2029 at his mid-single digits. The permanent agents market is further sub-segmented into particle agents, coils, liquid embolic agents, flow diverters, etc., among which the coil segment will account for the largest share in 2022, as follows: expected to grow. Low single digit CAGR from 2022 to 2029. Liquid Embolic Agents Market is expected to grow at CAGR from 2022 to 2029 in his early teens. Particle age nts are further segmented into polyvinyl alcohol (PVA) and microspheres, among which the microspheres segment will account for the largest share in 2022, growing at a high single-digit he CAGR from 2022 to 2029. It is expected that Coils are further segmented into pushable coils and detachable coils Among which, detachable coils will hold the largest share in 2022, and this segment will grow in low single digits from 2022 to 2029 is expected to grow at a CAGR of
The application market is segmented into Neurology, Oncology, Peripheral Vascular Disease, Urology, among others, among which the Neurology segment will account for the largest share at 44.5% in 2022, with single-digit growth from 2022 to 2029. It is expected to grow at a mid CAGR. This segment is expected to grow at a CAGR of high single digits from 2022 to 2029. The segment is expected to grow at a high single-digit CAGR from 2022 to 2029. The oncology market is further segmented into liver cancer, lung cancer, etc. Of which, the lung cancer segment will generate the largest revenue in 2022, and the market will grow at a high single-digit CAGR from 2022 to 2029. expected to grow.
Based on procedure, the global market for embolization therapy is divided into transcatheter arterial embolization (TAE), transcatheter arterial chemoembolization (TACE), and transcatheter arterial radioembolization (TARE)/selective internal radiation therapy (SIRT). split, of which TAE has the largest share in 2022. The market is expected to grow at a mid-single-digit CAGR from 2022 to 2029, and the TARE/SIRT segment is expected to grow at a high-single-digit CAGR from 2022 to 2029. There are bead-TACE and conventional his-TACE, of which cTACE will generate the largest revenue in 2022, and the market is expected to grow at his mid-single-digit CAGR from 2022 to 2029. increase.
The end-user market is segmented into hospitals, ambulatory surgery centers, and others. Among them, hospitals accounted for his largest share in 2022 and from 2022 he is expected to grow at his CAGR of high single digits through 2029. Ambulatory surgery centers are expected to grow at a CAGR of high single digits from 2022 to 2029.
Geographically, North America is the largest market, followed by Europe and Asia Pacific. The APAC region is the fastest growing region and is expected to grow at a high single digit CAGR from 2022 to 2029, presenting a variety of growth opportunities and attracting new investors in the embolization therapy market. It can attract attention. The growth of the Asian market is attributed to rising prevalence of lifestyle diseases and government initiatives to establish innovative technologies and demand for advanced medical services.
Factors such as the increasing number of chronically ill patients are increasing the demand for embolization and technological advancements are driving the market growth, while acquisitions and collaborations and emerging markets provide growth opportunities.
On the other hand, side effects, complications, risks, and lack of skilled and trained professionals associated with embolization are restraining market growth, while increasing product recalls, competition from alternative therapies, product development and Stringent regulatory requirements for approval threaten the market. growth.
The global embolization therapy market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market share. Major players in the embolization therapy market include Medtronic, PLC (Ireland), Microport Scientific (China), Boston Scientific Corporation (US), Stryker (US), Terumo Corporation (Japan), Penumbra, Inc. (US), Sirtex ( CDH) included. (China), Johnson & Johnson (US), Balt Group (France), Kaneka Corporation (Japan), Merit Medical (US), Cook Medical (US), Siemens Healthineers (Varian) (Germany), and Guerbet (France) .
Read the full report: https://www.reportlinker.com/p06377911/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you can instantly get all the market research you need in one place.
CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001